<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35836136</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study.</ArticleTitle><Pagination><StartPage>260</StartPage><MedlinePgn>260</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">260</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-022-02788-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease characterized by the gradual loss of upper and lower motor neurons that leads to progressive muscle atrophy and weakness. Edaravone, a free-radical scavenger, was approved as an ALS treatment in 2015 in South Korea.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study investigated the long-term effects and safety of edaravone by reviewing the medical records of 16 Korean patients with ALS who received extended edaravone between 2015 and 2021 in a single tertiary ALS center.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among sixteen patients, eleven patients underwent extended edaravone therapy for more than 18&#x2009;cycles (72&#x2009;weeks). The mean monthly changes in the revised ALS Functional Rating Scale (ALSFRS-R) were&#x2009;-&#x2009;0.96&#x2009;&#xb1;&#x2009;0.83 (0-24&#x2009;weeks), -&#x2009;0.70&#x2009;&#xb1;&#x2009;0.76 (24-48&#x2009;weeks), -&#x2009;1.18&#x2009;&#xb1;&#x2009;1.67 (48-72&#x2009;weeks), and&#x2009;-&#x2009;0.81&#x2009;&#xb1;&#x2009;0.60 (0-72&#x2009;weeks). The mean decline in forced vital capacity (FVC) was 17.4&#x2009;&#xb1;&#x2009;24.1. The changes were significant in both ALSFRS-R (p&#x2009;&lt;&#x2009;0.001) and FVC (p&#x2009;=&#x2009;0.048); however, the mean change in compound muscle action potential of phrenic nerves was not. Patients experienced only minor adverse events, which were well tolerated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study verifies previous reported outcomes of edaravone in 16 Korean ALS patients, indicating a modest effect with a favorable safety profile.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Mo</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Dongguk University College of Medicine, Dongguk University Gyeongju Hospital, Gyeongju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Donghwi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Ulsan University hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyung-Jun</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Dementia Research Group, Korea Brain Research Institute (KBRI), Daegu, 41068, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Sung</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-5506-9206</Identifier><AffiliationInfo><Affiliation>Dementia Research Group, Korea Brain Research Institute (KBRI), Daegu, 41068, Republic of Korea. neurojspark@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, 807 Hoguk-ro, Buk-gu, Daegu, 41404, Republic of Korea. neurojspark@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical><Chemical><RegistryNumber>T3CHA1B51H</RegistryNumber><NameOfSubstance UI="D000983">Antipyrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000983" MajorTopicYN="N">Antipyrine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse effect</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Edaravone</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35836136</ArticleId><ArticleId IdType="pmc">PMC9281019</ArticleId><ArticleId IdType="doi">10.1186/s12883-022-02788-x</ArticleId><ArticleId IdType="pii">10.1186/s12883-022-02788-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Park JM, Kim SY, Park D, et al. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci. 2020;41:119&#x2013;123. doi: 10.1007/s10072-019-04055-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04055-3</ArticleId><ArticleId IdType="pmc">PMC7223963</ArticleId><ArticleId IdType="pubmed">31471712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadinejad F, Geir Moller S, Hashemzadeh-Chaleshtori M, et al. Molecular mechanisms behind free radical scavengers function against oxidative stress. Antioxidants (Basel) 2017;6(3):51. doi: 10.3390/antiox6030051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox6030051</ArticleId><ArticleId IdType="pmc">PMC5618079</ArticleId><ArticleId IdType="pubmed">28698499</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J, Heiman-Patterson T, Pioro EP, et al. Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of study 19 (MCI186-19) Muscle Nerve. 2020;61:218&#x2013;221. doi: 10.1002/mus.26740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26740</ArticleId><ArticleId IdType="pmc">PMC7004197</ArticleId><ArticleId IdType="pubmed">31621933</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Moglia C, Lizio A, et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267:3258&#x2013;3267. doi: 10.1007/s00415-020-09993-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09993-z</ArticleId><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger VA. Controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Yamashita S, Ueyama H, et al. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci. 2018;11:11&#x2013;14. doi: 10.1016/j.ensci.2018.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.05.001</ArticleId><ArticleId IdType="pmc">PMC6006910</ArticleId><ArticleId IdType="pubmed">29928711</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Bovio G, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71:1134&#x2013;1142. doi: 10.1001/jamaneurol.2014.1129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1129</ArticleId><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Carrero JJ, Zagai U, et al. Blood biomarkers and prognosis of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:2125&#x2013;2133. doi: 10.1111/ene.14409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14409</ArticleId><ArticleId IdType="pubmed">32557963</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>